Dianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results, Beats Estimates By $0.04 EPS

Dianthus Therapeutics (NASDAQ:DNTH) announced its quarterly earnings data on Tuesday. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04, Zacks reports. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

Dianthus Therapeutics Stock Down 3.9 %

Dianthus Therapeutics stock traded down $0.96 during midday trading on Tuesday, reaching $23.38. 299,958 shares of the stock traded hands, compared to its average volume of 226,001. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77. The stock’s fifty day moving average is $22.56 and its 200-day moving average is $25.02. The stock has a market cap of $691.98 million, a P/E ratio of -9.35 and a beta of 1.82.

Wall Street Analyst Weigh In

Several research firms recently commented on DNTH. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $46.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.